(Q38077472)

28 August 2017

1 reference

title

Molecularly targeted therapies for metastatic triple-negative breast cancer (English)

1 reference

28 August 2017

1 reference

Soley Bayraktar

1

1 reference

28 August 2017

Stefan Glück

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

29 January 2013

1 reference

Breast Cancer Research and Treatment

28 August 2017

published in

1 reference

28 August 2017

volume

138

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

21-35

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-013-2421-5

28 August 2017

exact match

0 references

cites work

Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Directed therapy of subtypes of triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Reputation and precedent in the bevacizumab decision

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Triple-negative breast cancer: role of antiangiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

DNA repair pathways as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Triple-negative breast cancer: an unmet medical need

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Molecular mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Development of candidate genomic markers to select breast cancer patients for dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Biomarkers and multiple drug resistance in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Molecular stratification of triple-negative breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Deconstructing the molecular portraits of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Triple-negative breast cancer: risk factors to potential targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Src: a potential target for the treatment of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2421-5

10.1007/S10549-013-2421-5

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1043776195

0 references

1 reference